SLC5A2 and diabetes mellitus: In addition, the composite of cardiovascular death or HF hospitalizations was significantly lower in the SGLT2 inhibitor group among participants with diabetes (HR 0·74; 95% CI 0·68–0·80; p<0·0001; I2=0%; Supplementary Figure 8A) and without diabetes (HR 0·74; 95% CI 0·63–0·86; p = 0·0002; I2=0%; Supplementary Figure 8B).